Give more independence to the Scots—paired with a statement that there will be no more votes for a long time to come
The move comes as GM's blue-chip brand is finally considered in range of—if not quite on par with—the best German luxury rides
Unresolved economic conflicts simmer during a tenuous cease-fire
In becoming Oracle's chairman and chief technology officer, Ellison will leave the software giant he founded in the hands of co-chief executive officers Mark Hurd and Safra Katz
The popular premixed funds are supposed to get more conservative as retirement gets closer. What “conservative” means is open to interpretation
With "activity-based working," you lose your desk and gain your freedom—all for better efficiency
The NFL is facing its worst crisis in 50 years. Why is Commissioner Goodell so sure he won't lose his job?
Two dozen live shows will broadcast professors' ideas for 40 hours a week, serving as a way to broaden Wharton's reach
A report finds high default rates on franchise loans
Founders: Dr. Daniel J. Abrams; Tom Anchordoquy, PhD; and Karen Stevens, PhD
VC Investment over the last four quarters: $21.5 million
Founded in 2005, this seven-person biopharmaceutical company develops drugs for the treatment of severe central nervous system diseases. In addition to VC funding, Sierra received about $230,000 in grants from the State of Colorado, the University of Colorado, and the Coleman Institute. As for the recession, its founders say the company will be keeping close tabs on the funding and partnership environment over the next two to three years, despite already being funded for drug development work for the next three years.
Key to startup success: "Be persistent in the development of your data and business model to enable you to create a financial model that has a high likelihood of helping patients and therefore is fundable by the investor community."